Thyroid cancer

Maria E. Cabanillas, David G. McFadden, Cosimo Durante

Research output: Contribution to journalReview article

168 Citations (Scopus)

Abstract

Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.

Original languageEnglish (US)
Pages (from-to)2783-2795
Number of pages13
JournalThe Lancet
Volume388
Issue number10061
DOIs
StatePublished - Dec 3 2016

Fingerprint

Thyroid Neoplasms
Iodine
Disease-Free Survival
Neoplasms
Thyroid Gland
Observation
Physicians
Incidence
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cabanillas, M. E., McFadden, D. G., & Durante, C. (2016). Thyroid cancer. The Lancet, 388(10061), 2783-2795. https://doi.org/10.1016/S0140-6736(16)30172-6

Thyroid cancer. / Cabanillas, Maria E.; McFadden, David G.; Durante, Cosimo.

In: The Lancet, Vol. 388, No. 10061, 03.12.2016, p. 2783-2795.

Research output: Contribution to journalReview article

Cabanillas, ME, McFadden, DG & Durante, C 2016, 'Thyroid cancer', The Lancet, vol. 388, no. 10061, pp. 2783-2795. https://doi.org/10.1016/S0140-6736(16)30172-6
Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. The Lancet. 2016 Dec 3;388(10061):2783-2795. https://doi.org/10.1016/S0140-6736(16)30172-6
Cabanillas, Maria E. ; McFadden, David G. ; Durante, Cosimo. / Thyroid cancer. In: The Lancet. 2016 ; Vol. 388, No. 10061. pp. 2783-2795.
@article{53a90711cd1c4169a19e520ecd0d2b59,
title = "Thyroid cancer",
abstract = "Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.",
author = "Cabanillas, {Maria E.} and McFadden, {David G.} and Cosimo Durante",
year = "2016",
month = "12",
day = "3",
doi = "10.1016/S0140-6736(16)30172-6",
language = "English (US)",
volume = "388",
pages = "2783--2795",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10061",

}

TY - JOUR

T1 - Thyroid cancer

AU - Cabanillas, Maria E.

AU - McFadden, David G.

AU - Durante, Cosimo

PY - 2016/12/3

Y1 - 2016/12/3

N2 - Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.

AB - Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.

UR - http://www.scopus.com/inward/record.url?scp=84970004218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970004218&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(16)30172-6

DO - 10.1016/S0140-6736(16)30172-6

M3 - Review article

C2 - 27240885

AN - SCOPUS:84970004218

VL - 388

SP - 2783

EP - 2795

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10061

ER -